CJMB's Full-Year Update Highlights Narrative Over Substance Amid Persistent Financial Weaknesses

What happened

Callan JMB issued a press release reporting full-year 2025 results, emphasizing deepened government relationships and momentum in healthcare and food manufacturing. However, the DeepValue master report reveals that prior SEC filings show revenue plummeted from $13.2 million in FY2023 to $6.6 million in FY2024, with a net loss and negative operating cash flow of $(3.9) million for nine months ended September 2025. The company's growth narratives around GLP-1 cold-chain and federal deployment remain unsubstantiated in regulatory documents, lacking quantified retrofit capex or signed customer contracts. High customer concentration and reliance on a punitive equity line, priced at 95% of the lowest trading price, continue to pose dilution risks. Investors should view the optimistic press release skeptically until verifiable evidence emerges in upcoming SEC filings.

Implication

The press release does not alter the fundamental weaknesses identified in the DeepValue report, such as revenue volatility and cash burn. Claims of government and healthcare progress require validation through future filings showing awarded contracts or retrofit milestones. Without such evidence, equity line usage may accelerate, increasing dilution and pressuring share prices. Customer concentration remains a critical vulnerability, evidenced by the FY2024 revenue collapse from a single account suspension. Therefore, the investment call stays at WAIT, with re-assessment dependent on concrete regulatory disclosures rather than press releases.

Thesis delta

The new press release does not shift the investment thesis. The DeepValue report's WAIT rating remains appropriate, as the update provides no SEC-filed quantification of Texas retrofit capex or signed pharma revenue. Investors should continue to monitor upcoming filings for evidence that could change the call.